Immunology of Chronic Fatigue Syndrome

References

• Shanks N, Francis D, Zalcman S, Meaney MJ, Anisman H: Alterations in central cathecolamines associated with immune responses in adult and aged mice. Brain Res 666(1):77–87, 1994.
   PubMed Web of Science ®Google Scholar
• Besedovsky H, del Rey A, Sorkien E, Da Prada M, Burn i R, Honegger C: The immune response evokes changes in brain noradrenergic neurons. Science 221(4610):564–566, 1983.
   PubMed Web of Science ®Google Scholar
• Vasina IG, Frolov EP, Serebriakov NG: Sympathico-adrenal system activity in a primary immune response. Zhurnal Mikrobiologii, Epidemiologii i Imunobiolo-gii 10(9):88–92, 1975.
   PubMedGoogle Scholar
• Boranic M: The central nervous system and immunity. Lijecnicki Vjesnik 112(9-10):329–334, 1990.
   PubMedGoogle Scholar
• Boranic M, Pericic D, Radacic M, Poljak-Blasi M, Sverko V, Miljenovic G: Immunological and neuroendocrine responses of rats to prolonged or repeated stress. Biomedicine & Pharmacotherapy 36(1):23–28, 1982.
   PubMed Web of Science ®Google Scholar
• Basso AM, Depiante-Depaoli M, Molina VA: Chronic variable stress facilitates tumoral growth: reversal by imipramine administration. Life Sciences 50(23):1789–1796, 1992.
   PubMed Web of Science ®Google Scholar
• Foley FW, Traugott U, LaRocca NG, Smith CR, Perlman KR, Caruso LS, Scheinberg LC: A prospective study of depression and immune dysregulation in mul-tiple sclerosis. Arch Neurol 49(3):238–244, 1992.
   PubMed Web of Science ®Google Scholar
• De Souza EB: Corticotropin-releasing factor and interleukin-1 receptors in the brain-endocrine-immune axis. Role in stress response and infection. Annals of the New York Academy of Sciences 697:9-27, 1993.
   Google Scholar
• Irwin M: Stress-induced immune suppression. Role of the autonomic nerv-ous system. Annals of the New York Academy of Sciences 697:203–218, 1993.
   PubMed Web of Science ®Google Scholar
• Weiss JM, Quan N, Sundar SK Widespread activation and consequences of interleukin-1 in the brain. Annals of the New York Academy of Sciences 741:338–357, 1994.
   PubMed Web of Science ®Google Scholar
• Hebert TB, Cohen S: Depression and immunity: a meta-analytic review. Psychol Bull 113:472–486, 1993.
   PubMed Web of Science ®Google Scholar
• Irwin M, Patterson T, Smith TL, Caldwell C, Brown SA, Gillin JC, Grant I: Reduction of immune function in life stress and depression. Biological Psychiatry 27:222–230, 1990.
   Google Scholar
• Irwin M, Caldwell C, Smith TL, Brown S, Schuckit MA, Gillin C: Major depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity. Archives of General Psychiatry 47:713–719, 1990.
   PubMed Web of Science ®Google Scholar
• Schleifer SJ, Keller SE, Bond RN, Cohen J, Stein M: Major depressive dis-order: role of age, sex, severity and hospitalization. Achives of general Psychiatry 46:81–87, 1989.
   PubMed Web of Science ®Google Scholar
• Lechin F, van der Dijs B, Acosta E, Gomez F, Lechin E, Arocha L: Distal colon motility and clinical parameters in depression. J Afect Dis 5:19–26, 1983.
   PubMed Web of Science ®Google Scholar
• Lechin F, van der Dijs B, Gomez F, Arocha L, Acosta E, Lechin E: Distal colon motility as a predictor of antidepressant response to fenfluramine, imipramine and clomipramine. J Affect Dis 5:27–35, 1983.
   PubMed Web of Science ®Google Scholar
• Lechin F, van der Dijs, Jakubowicz D, et al: Effects of clonidine on blood pressure, noradrenaline, cortisol, growth hormone and prolactin plasma levels in low and high intestinal tone depressed patients. Neuroendocrinology 41:156–162, 1985.
   PubMed Web of Science ®Google Scholar
• Lechin F, van der Dijs B, Jakubowicz D, et al: Role of stress in the exacerba-tion of chronic illness: Effects of clonidine administration on blood pressure and plasma norepinephrine, cortisol, growth hormone and prolactin concentrations. Psy-choneuroendocrinology 12:117–129, 1987.
   PubMed Web of Science ®Google Scholar
• Lechin F, van der Dijs B, Amat J, Lechin M: Central neuronal pathways in-volved in depressive syndrome: Experimental findings. In Neurochemistry, and Clini-cal Disorders: Circuitry of Some Psychiatric and Psychosomatic Syndromes. Lechin F, van der Dijs B (eds.). Boca Raton, FL, CC press, 1989, pp. 65–89.
   Google Scholar
• Lechin F, van der Dijs B, Lechin A, et al: Plasma neurotransmitters and cor-tisol in chronic illness: Role of stress. J Med 25:181–192, 1994.
   PubMedGoogle Scholar
• Patarca R, Fletcher MA, Klimas NG: Immunological correlates of the chron-ic fatigue syndrome. In Chronic Fatigue Syndrome, P Goodnick, NG Klimas (eds.). Washington, American Psychiatric Press, 1992, pp. 1–21.
   Google Scholar
• Sobel RA, Hafler DA, Castro EE, et al: The 2114 (CD45R) antigen is selec-tively decreased in multiple sclerosis lesions. J Immunol 140:2210–2214, 1988.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Wener MH, Pearlman T, Kith P: Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. Journal of Rheu-matology 24(2):372–6, 1997.
   PubMed Web of Science ®Google Scholar
• Patarca R, Klimas NG, Garcia MN, Pons H, Fletcher MA: Dysregulated ex-pression of soluble immune mediator receptors in a subset of patients with chronic fatigue syndrome: Categorization of patients by immune status. Journal of Chronic Fatigue Syndrome 1:79–94, 1995.
   Google Scholar
• Patarca R, Klimas NG, Sandler D, Garcia MN, Fletcher MA: Interindividual immune status variation patterns in patients with chronic fatigue syndrome: associa-tion with the tumor necrosis factor system and gender. Journal of Chronic Fatigue Syndrome 2(1):13–19, 1995.
   Google Scholar
• Goldie AS, Fearon KCH, Ross JA, Barclay R, Jackson RE, Grant IS, Ramsay G, Blyth AS, Howie JC, The Sepsis Intervention Group. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 274:172–177, 1995.
   Google Scholar
• Cantor H, Boyse EA: Regulation of cellular and humoral immune responses by T-cell subclasses. Cold Spring Harbor Symp Quant Biol 41:23–32, 1977.
   PubMedGoogle Scholar
• Reinherz EL, Schlossman SF: The characterization and function of human immunoregulatory T lymphocyte subsets. Immunology Today 2:6975–6979, 1981.
   Google Scholar
• Romain P, Schlossman S: Human T lymphocyte subsets. Functional hetero-geneity and surface recognition structures. J Clin Invest 74:1559–1565, 1984.
   Google Scholar
• Calabrese JR, Kling MA, Gold PA: Alterations in immunocompetence dur-ing stress, bereavement, and depression: focus on neuroendocrine regulation. Am J Psychiatry 144:1123–1134, 1987.
   PubMed Web of Science ®Google Scholar
• Fletcher MA, Azen S, Adelberg B, et al: Immunophenotyping in a multicenter study: the transfusion safety experience. Clin Immunol Immunopatol 52:38–47, 1989.
   PubMedGoogle Scholar
• Griffin DE: Immunologic abnormalities accompanying acute and chronic vi-ral infections. Rev Infect Dis 13(1):5129–5133, 1991.
   Google Scholar
• Klimas N, Patarca R, Perez G, et al: Distinctive immune abnormalities in a patient with procainamide-induced lupus and serositis. Am J Med Sci 303(2):1–6, 1992.
   PubMedGoogle Scholar
• McAllister CG, Rapaport MH, Pickar D, et al: Increased numbers of CD5+ B lymphocytes in schizophrenic patients. Arch Gen Psychiatry 46:890–894, 1989.
   PubMed Web of Science ®Google Scholar
• Raziuddin S, Elawad ME: Immunoregulatory CD4+CD45R+ suppressor/in-ducer T lymphocyte subsets and impaired cell-mediated immunity in patients with Down's syndrome. Clin Exp Immunol 79:67–71, 1990.
   PubMed Web of Science ®Google Scholar
• Villemain F, Chatenoud L, Galinowski A, et al: Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production. Am J Psychiatry 146:609–616, 1989.
   PubMed Web of Science ®Google Scholar
• Herberman RB: Sources of confounding in immunologic data. Rev Infect Dis 13(1):584–586, 1991.
   Google Scholar
• Lahita RG: Sex hormones and immunity. In Basic and Clinical Immunology, DP, Stobo JD, Fudenberg HI, et al. (eds.), Los Altos, CA, Lange, 1982, pp. 293–294.
   Google Scholar
• Malone JL, Simms TE, Gray GC, et al: Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected pa-tients: total lymphocyte count fluctutations and diurnal cycle are important. Journal of Acquired Immune Deficiency Syndromes 3:144–151, 1990.
   PubMed Web of Science ®Google Scholar
• Martin E, Muler JV, Dionel C: Disappearance of CD4 lymphocyte circadian cycles in HIV-infected patients: early event during asymptomatic infection. AIDS 2:133–134, 1988.
   PubMed Web of Science ®Google Scholar
• Patarca R, Sandler D, Walling J, Klimas NG, Fletcher MA: Assessment of immune mediator expression levels in biological fluids and cells: a critical appraisal. Critical Reviews in Oncogenesis 6(2):117–149, 1995.
   PubMed Web of Science ®Google Scholar
• Roberts TK, McGregor NR, Dunstan RH, Donohoe M, Murdoch RN, Hope D, Zhang S, Butt HL, Watkins JA, Taylor WG: Immunological and haematological parameters in patients with chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome 4(4):51–66, 1998.
   Google Scholar
• Schulte PA: Validation of biologic markers for use in research on chronic fatigue syndrome. Rev Infect Dis 13:S87–S89, 1991.
   PubMedGoogle Scholar
• Whiteside TL: Cytokine measurements and interpretation in human dis-ease. J Clin Immunol 14:327–339, 1994.
   PubMed Web of Science ®Google Scholar
• Straus SE, Tosato G, Armstrong G, et al: Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 102:7–16, 1985.
   PubMed Web of Science ®Google Scholar
• Jones J: Serologic and immunologic responses in chronic fatigue syndrome with emphasis on the Epstein-Barr virus. Rev Infect Dis 13(1):526–531, 1991.
   Google Scholar
• Jones JF, Straus SE: Chronic Epstein-Barr virus infection. Annu Rev Med 38:195–209, 1987.
   PubMed Web of Science ®Google Scholar
• Jones JF, Ray G, Minnich LL, et al: Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early anti-gen antibodies. Ann Intern Med 102:1–7, 1985.
   PubMed Web of Science ®Google Scholar
• Borysiewicz LK, Haworth SJ, Cohen J, et al: Epstein-Barr virus-specific immune defects in patients with persistent symptoms following infectious mononu-cleosis. Q J Med 58:111–121, 1986.
   PubMedGoogle Scholar
• Gupta S, Vayuvegula B: A comprehensive immunological analysis in chron-ic fatigue syndrome. Scand J Immunol 33(3):319–327, 1991.
   PubMed Web of Science ®Google Scholar
• Landay AL, Jessop C, Lennette ET, Levy JA: Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 338:707–712, 1991.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Hickie I, Hickie C, Dwyer J, Wakefield D: Cell-mediated immuni-ty in patients with chronic fatigue syndrome, healthy controls and patients with major depression. Clin exp Immunol 87(1):76–79, 1992.
   PubMed Web of Science ®Google Scholar
• Tirelli U, Marotta G, Improta S, Pinto A: Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 40(6):601–608, 1994.
   PubMed Web of Science ®Google Scholar
• Lloyd AR, Wakefield D, Boughton CR, et al: Immunological abnormalities in the chronic fatigue syndrome. Med J Aust 151:122–124, 1989.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Komaroff AL: Review of laboratory findings for patients with chronic fatigue syndrome. Rev Infect Dis 13(1):512–518, 1991.
   Google Scholar
• Klimas N, Salvato F, Morgan R, Fletcher MA: Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 28(6):1403–1410, 1990.
   PubMed Web of Science ®Google Scholar
• Aoki T, Usuda Y, Miyakashi H, et al: Low natural syndrome: clinical and immunologic features. Nat Immun Cell Growth Regul 6:116–128, 1987.
   PubMedGoogle Scholar
• DuBois RE: Gamma globulin therapy for chronic mononucleosis syndrome. AIDS Res Hum Retroviruses 2(1):5191–5195, 1986.
   Google Scholar
• Linde A, Hammarstrom L, Smith CIE: IgG subclass deficiency and chronic fatigue syndrome. Lancet 1:885–886, 1988.
   PubMed Web of Science ®Google Scholar
• Mawle AC, Nisenbaum R, Dobbins JG, Gary HE Jr, Stewart JA, Reyes M, Steele L, Schmid DS, Reeves WC: Immune responses associated with chronic fatigue syndrome: A case-control study. Journal of Infectious Diseases 175(4136–141, 1997.
   Google Scholar
• Patarca R, Goodkin K, Fletcher MA: Cryopreservation of peripheral blood mononuclear cells. In Manual of Clinical Laboratory Immunology, Rose NR, de Ma-cario EC, Folds JD, Lane HC, Nakamura RM (Eds.), 1995.
   Google Scholar
• Sandman CA, Barron JL, Nackoul KA, Fidler PL, Goldstein J: Is there a chronic fatigue syndrome (CFS) dementia. In The Clinical and Scientific Basis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Hyde B, Levine P, Goldstein J (eds.). Nightingale Research Foundation. Ottawa Canada, 1992, pp. 467–479.
   Google Scholar
• Morimoto C, Letvin NL, Distaso JA, et al: The isolation and characterization of the human suppressor inducer T cell subset. J Immunol 134: 1508–1512, 1985.
   PubMed Web of Science ®Google Scholar
• Natelson BH, LaManca JJ, Denny TN, Vladutiu A, Oleske J, Hill N, Bergen MT, Korn L, Hay J: Immunologic parameters in chronic fatigue syndrome, major de- pression, and multiple sclerosis. American Journal of Medicine 105(3A):43S-49S, 1998.
   Google Scholar
• Franco K, Kawa HA, Doi S, et al: Remarkable depression of CD4+2H4+ T cells in severe chronic active Epstein-Barr virus infection. Scand J Immunol 26:769–773, 1987.
   PubMed Web of Science ®Google Scholar
• Alpert S, Kloide J, Takada S, et al: T cell regulatory disturbances in the rheu-matic diseases. Rheum Dis Clin North Am 13(3):431–435, 1987.
   PubMed Web of Science ®Google Scholar
• Emery P, Gently KC, Mackay IR, et al: Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis. Arthitis Rheum 30: 849–856, 1987.
   PubMed Web of Science ®Google Scholar
• Sato K, Miyasaka N, Yamaoka K, et al: Quantitative defect of CD4+2H4+ cells in systemic lupus erythematosus and Sjogren's syndrome. Arthritis Rheum 30:1407–1411, 1987.
   PubMed Web of Science ®Google Scholar
• Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA: Immunologic ab-normalities associated with chronic fatigue syndrome. Clin Infect Dis 18\(supp 1): S136-S141, 1994.
   Google Scholar
• Hassan IS, Bannister BA, Akbar A, Weir W, Bofill M: A study of the im-munology of the chronic fatigue syndrome: Correlation of immunologic markers to health dysfunction. Clinical Immunology & Immunopathology 87(1):60–67, 1998.
   PubMedGoogle Scholar
• Swanink CM, Vercoulen JH, Galama JM, Roos MT, Meyaard L, van der Ven-Jongekrijg J, de Nijs R, Bleijenberg G, Fennis JF, Miedema F, van der Meer JW: Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syn-drome. Journal of Infectious Diseases 173(2):460–463, 1996.
   PubMed Web of Science ®Google Scholar
• Peakman M, Deale A, Field R, Mahalingam M, Wessely S: Clinical im-provement in chronic fatigue syndrome is not associated with lymphocyte subsets of function or activation. Clinical Immunology & Immunopathology 82(1):83–91, 1997.
   PubMedGoogle Scholar
• Alviggi L, Johnson C, Hopkins PJ, et al: Pathogenesis of insulin-dependent diabetes: a role for activated T lymphocytes. Lancet 2:4–6, 1984.
   PubMed Web of Science ®Google Scholar
• Canonina GW, Bagnasco M, Corte G, et al: Circulating T lymphocytes in Hashimoto's disease: imbalance of subsets and presence of activated cells. Clin Im-munol Immunopathol 23:616–625, 1982.
   PubMedGoogle Scholar
• Jackson RA, Haynes BF, Burch WM, et al: Ia+ T cells in new onset Grave's disease. J Clin Endocrinol Metab 59:187–190, 1984.
   PubMed Web of Science ®Google Scholar
• Koide J: Functional property of Ia-positive T cells in peripheral blood from patients with systemic lupus erythematosus. Scand J Immunol 22:577–584, 1985.
   PubMed Web of Science ®Google Scholar
• Rabinowe SL, Jackson RA, Dluhy RG, et al: Ia-positive T lymphocytes in recently diagnosed idiopathic Addison's disease. Am J Med 77:597–601, 1984.
   PubMed Web of Science ®Google Scholar
• Helder L, Wagner S, Keller R, Klimas N, Antoni M: Markers of immune activation are associated with psychological distress in patients with CFS. Abstract, IV AACFS meeting, Cambridge, MA, 1998.
   Google Scholar
• Casali P, Notkins AL: CD5+ B lymphocytes, polyreactive antibodies and the human B cell repertoire. Immunology Today 10:364–368, 1989.
   PubMedGoogle Scholar
• Morrison LJ, Behan WH, Behan PO: Changes in natural killer cell pheno-type in patients with post-viral fatigue syndrome. Clin Exp Immunol 83:441–446, 1991.
   PubMed Web of Science ®Google Scholar
• Masuda A, Nozoe SI, Matsuyama T, Tanaka H: Psychobehavioral and im-munological characteristics of adult people with chronic fatigue and patients with chronic fatigue syndrome. Psychosom Med 56(6):516–518, 1994.
   Google Scholar
• Caligiuri M, Murray C, Buchwald D, Levine H, Cheney P, Peterson D, Ko-maroff AL, Kitz J: Phenotypic and functional deficiency of natural killer cells in pa-tients with chronic fatigue syndrome. J Immunol 139(10):3306–3313, 1987.
   PubMed Web of Science ®Google Scholar
• Cannon JG, Angel JB, Abad LW, O'Grady J, Lundgren N, Fagioli L, Komar-off AL: Hormonal influences on stress-induced neutrophil mobilization in health and chronic fatigue syndrome. Journal of Clinical Immunology 18(4):291–298, 1998.
   PubMed Web of Science ®Google Scholar
• Behan PO, Behan WHM, Bell EJ: The postviral fatigue syndrome-An anal-ysis of the findings in 50 cases. J Infect 1985;10:211-22, 1985.
   Google Scholar
• Tobi M, Morag A, Ravid Z, et al: Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr infection. Lancet 1:61–64, 1982.
   PubMed Web of Science ®Google Scholar
• Subira ML, Castilla A, Civeira MP, et al: Deficient display of CD3 on lym-phocytes of patients with chronic fatigue syndrome. J Infect Dis 160:165–166, 1989.
   PubMed Web of Science ®Google Scholar
• Olson GB, Kanaan MN, Gersuk GM, et al: Correlation between allergy and persistent Epstein-Barr virus infections in chronic active Epstein-Barr virus infected patients. J Allergy Clin Immunol 78:308–314, 1986.
   PubMed Web of Science ®Google Scholar
• Olson GB, Kanaan MN, Kelley LM, et al: Specific allergen-induced Eps-tein-barr nucler antigen-positive B cells from patients with chronic active Epstein-Barr virus infections. J Allergy Clin Immunol 78:315–320, 1986.
   PubMed Web of Science ®Google Scholar
• Lutgendorf S, Klimas NG, Antoni M, Brickman A, Fletcher MA: Relation-ships of cognitive difficulties to immune measures, depression and illness burden in chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome 1(2):23–41, 1995.
   Google Scholar
• Vojdani A, Ghoneum M, Choppa PC, Magtoto L, Lapp CW: Elevated apop-totic cell population in patients with chronic fatigue syndrome: The pivotal role of protein kinase RNA. Journal of Internal Medicine 242(6):465–478, 1997.
   PubMed Web of Science ®Google Scholar
• See DM, Cimoch P, Chou S, Chang J, Tilles J: The in vitro immunodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome. Integrative Physiological & Behavioral Science 33(3): 280–287, 1998.
   PubMed Web of Science ®Google Scholar
• Kibler R, Lucas DO, Hicks M, et al: Immune function in hronic active Eps-tein-Barr virus infection. J Clin Immunol 5:46–54, 1985.
   PubMed Web of Science ®Google Scholar
• Ojo-Amaise EA, Conley EJ, Peters JB: Decreased natural killer cell activity is associated with severity of chronic fatigue immune deficiency syndrome. Clin Inf Dis 18:S157–S159, 1994.
   PubMed Web of Science ®Google Scholar
• See DM, Broumand N, Sahl L, Tilles JG: In vitro effect of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome. Immuno-pharmacology 35:229–235, 1997.
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Friberg D: Natural killer cells and natural killer cell activity in chronic fatigue syndrome. American Journal of Medicine 1998; 105(3A):275–345, 1998.
   Google Scholar
• Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G, Herberman RB: Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clinical Immunology & Immunopathology 88(1):96–104 1998.
   PubMedGoogle Scholar
• Gold D, Bowden R, Sixbey J, et al: Chronic fatigue. A prospective clinical and virologic study. JAMA 264:48–53, 1990.
   Google Scholar
• Altman C, Larratt K, Golubjatnikov R, et al: Immunologic markers in the chronic fatigue syndrome. Clin Res 36:845A, 1988.
   Google Scholar
• Mode S, Castilla A, Civeira M-P, Serrano M, Prieto J: Gamma-interferon and chronic fatigue syndrome. Lancet 2:623–624, 1988.
   Web of Science ®Google Scholar
• Visser J, Blauw B, Hinloopen B, Brommer E, de Kloet ER, Kluft C, Nagel-kerken L: CD4 T lymphocytes from patients with chronic fatigue syndrome have de-creased interferon-gamma production and increased sensitivity to dexamethasone. Journal of Infectious Diseases 177(2):451–454, 1998.
   Google Scholar
• Morag A, Tobi M, Ravid Z, et al: Increased (2'-5')-oligo-a synthetase activi-ty in patients with prolonged illness associated with serological evidence of persis-tent Epstein-barr virus infection. Lancet 1:744, 1982.
   PubMed Web of Science ®Google Scholar
• Lusso P, Salahuddin SZ, Ablashi DV, et al: Diverse tropism of HBLV (hu-man herpesvirus 6). Lancet 2(8561):743, 1987.
   Google Scholar
• Glaser R, Kiecolt-Glaser JK: Stress-associated immune modulation: Rele-vance to viral infections and chronic fatigue syndrome. American Journal of Medi-cine 105(3A):355-425, 1998.
   Google Scholar
• Ogawa M, Nishiura T, Yoshimura M, Horikawa Y, Yoshida H, Okajima Y, Matsumura I, Ishikawa J, Nakao H, Tomiyama Y, Kanayama Y, Kanakura Y, Matsu-zawa Y: Decreased nitric oxide-mediated natural killer cell activation in chronic fa-tigue syndrome. European Journal of Clinical Investigation 28(11):937–943, 1998.
   PubMed Web of Science ®Google Scholar
• See DM, Tilles JG: Alpha-interferon treatment of patients with chronic fa-tigue syndrome. Immunological Investigations 25(1-2):153–164, 1996.
   PubMed Web of Science ®Google Scholar
• Aoki T, Usada Y, Miyakoshi H: A novel immunodeficiency: Low NK syn-drome (LNKS). Jap J Med 3212:14–17, 1985.
   Google Scholar
• Miyakoshi H, Aoki T, Mizukoshi: Acting mechaanisms of Lentinan in hu-mans. II. Enhancement of non-specific cell-mediated cytotoxicity as an interferon in-duced response. Int J Immunopharmacol 6:373–379, 1984.
   Google Scholar
• Prieto J, Subira ML, Castilla A, et al: Naloxone-reversible monocyte dysfunc-tion in patients with chronic fatigue syndrome. Scand J Immunol 30:13–20, 1989.
   PubMed Web of Science ®Google Scholar
• Gupta S, Aggarwal S, See D, Starr A: Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome. Journal of Psychiatric Research 31(1):149–156, 1997.
   PubMed Web of Science ®Google Scholar
• Conti F, Magrini L, Priori R, Valesini G, Bonini S: Eosinophil cationic pro-tein serum levels and allergy in chronic fatigue syndrome. Allergy 51(2):124–127, 1996.
   PubMed Web of Science ®Google Scholar
• Steinberg P, Pheley A, Peterson PK: Influence of immediate hypersensitivity skin reaction on delayed reactions in patients with chronic fatigue syndrome. Journal of Allergy & Clinical Immunology 98(6 Pt 1):1126–1128, 1996.
   Google Scholar
• Steinberg P, McNutt BE, Marshall P, Schenck C, Lurie N, Pheley A, Peter-son PK: Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome. Journal of Allergy & Clinical Immunolo-gy 97(1 Pt 1):119–126, 1996.
   Google Scholar
• Baraniuk JN, Clauw D, MacDowell-Carneiro AL, Bellanti J, Pandiri P, Foong S, Ali M: IgE concentrations in chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome 4(1):13–22, 1998.
   Google Scholar
• Baraniuk JN, Clauw DJ, Gaumond E: Rhinitis symptoms in chronic fatigue syndrome. Annals of Allergy, Asthma, & Immunology 81(4):359–65, 1998.
   PubMed Web of Science ®Google Scholar
• Borish L, Schmaling K, DiClementi JD, Streib J, Negri J, Jones JF: Chronic fatigue syndrome: Identification of distinct subgroups on the basis of allergy and psychologic variables. Journal of Allergy & Clinical Immunology 102(2):222–230, 1998.
   PubMed Web of Science ®Google Scholar
• Borok G: Chronic fatigue syndrome: An atopic state. Journal of Chronic Fa-tigue Syndrome 4(3):39–58, 1998.
   Google Scholar
• Vollmer-Conna U, Lloyd A, Hickie I, Wakefield D: Chronic fatigue syn-drome: An immunological perspective. Australian & New Zealand Journal of Psy-chiatry 32(4):523–527, 1998.
   PubMed Web of Science ®Google Scholar
• Sheng WS, Hu S, Lamkin A, Peterson PK, Chao CC: Susceptibility to im-munologically mediated fatigue in C57BL/6 versus Balb/c mice. Clinical Immunolo-gy & Immunopathology 81(2):161–167, 1996.
   Google Scholar
• Rook GA, Zumla A: Gulf War syndrome: Is it due to a systemic shift in cyto-kine balance towards a Th2 profile? Lancet 349(9068):1831–1833, 1997.
   Google Scholar
• Vojdani A, Lapp CW: Interferon-induced proteins are elevated in blood sam-ples of patients with chemically or virally induced chronic fatigue syndrome. Immu-nopharm Immunotoxicol 21(2):175–202, 1999.
   PubMed Web of Science ®Google Scholar
• Klimas NG, Fletcher MA: Alteration of type 1/type 2 cytokine pattern fol-lowing adoptive immunotherapy of patients with chronic fatigue syndrome (CFS) us-ing autologous ex vivo expanded lymph node cells. Abstract, II International Conf. CFS, Brussels, 1999.
   Google Scholar
• Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 77(8): 1627–1652, 1991.
   Google Scholar
• Platanias LC, Vogelzang NJ: Interleukin-1: Biology, pathophysiology, and clinical prospects. Am J Med 89:621–629, 1990.
   PubMed Web of Science ®Google Scholar
• Patarca R, Lugtendorf S, Antoni M, Klimas NG, Fletcher MA: Dysregulated expression of tumor necrosis factor in the chronic fatigue immune dysfunction syn-drome: Interrelations with cellular sources and patterns of soluble immune mediator expression. Clinical Infectious Diseases 18:S147–S153, 1994.
   PubMed Web of Science ®Google Scholar
• Linde A, Andersson B, Svenson SB, Ahrne H, Carlsson M, Forsberg P, Hugo H, Karstop A, Lenkei R, Lindwall A, et al: Serum levels of lymphokines and soluble cellular receptors in primary EBV infection and in patients with chronic fatigue syn-drome. J Inf Dis 165:994–1000, 1992.
   PubMed Web of Science ®Google Scholar
• Rasmussen AK, Nielsen AH, Andersen V, Barington T, Bendtzen K, Hansen MB, Nielsen L, Pederson BK, Wiik A: Chronic fatigue syndrome-a controlled cross sectional study. J Rheumatol 21(8):1527–1531, 1994.
   PubMed Web of Science ®Google Scholar
• Morte S, Castilla A, Civeira MP, Serrano M, Prieto J: Production of interleu-kin-1 by peripheral blood mononuclear cells in patients with chronic fatigue syn-drome. J. Infect Dis 159:362, 1989.
   Google Scholar
• Straus SE, Dale JK, Peter JB, Dinarello CA: Circulating lymphokine levels in the chronic fatigue syndrome. J Inf Dis 160(6):1085–1086, 1989.
   PubMed Web of Science ®Google Scholar
• Arnason BGW: Nervous system-immune system communication. Rev In-fect Dis 13(1):S134–S137, 1991.
   PubMedGoogle Scholar
• Berkenbosch F, J Van Oers, A Del Rey, et al: Corticotropin-releasing fac-tor-producing neurons in the RT activated by interleukin-1. Science 238:524–526, 1987.
   PubMed Web of Science ®Google Scholar
• Besedovsky H, Del Rey A, Sorkin E, et al: Immunoregulatory feedback be-tween interleukin-1 and glucocorticoid hormones. Science 1986; 233:652-654, 1986.
   Google Scholar
• Sapolsky R, Rivier C, Yamamoto G, et al: Interleukin-1 stimulates the secre-tion of hypothalamic corticotropin-releasing factor. Science 233:522–524, 1987.
   Google Scholar
• Bernton EW, Beach J, Holaday JW, et al: Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science 238:519–521, 1987.
   PubMed Web of Science ®Google Scholar
• Rettori V, Gimeno MF, Karara A, et al: Interleukin la inhibits protaglandin E2 release to suppress pulsatile release of luteinizing hormone but not follicle-stimu-lating hormone. Proc Natl Acad Sci USA 88:2763–2767, 1991.
   PubMed Web of Science ®Google Scholar
• Shoham S, Davenne D, Cady AB, et al: Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep. Am J Physiol 253:R142–R149, 1987.
   PubMed Web of Science ®Google Scholar
• Holmes GP, Kaplan JE, Gantz NM, et al: Chronic fatigue syndrome: A working cased definition. Ann Intern Med 108:387–389, 1988.
   PubMed Web of Science ®Google Scholar
• Moldovsky H: Nonrestorative sleep and symptoms after a febrile illness in patients with fibrosis and chronic fatigue syndrome. J Rheumatol 16(19):150–153, 1989.
   Google Scholar
• Van Eldik LJ, Zimmer DB: Secretion of S-100 from rat C6 glioma cells. Brain Res 436:367–370, 1987.
   PubMed Web of Science ®Google Scholar
• Griffin WST, Stanley LC, Ling C, et al.: Brain interleukin 1 and S-100 im-munoreactivity are elevated in Down's syndrome and Alzheimer's disease. Proc Natl Acad Sci USA 86:7611–7615, 1989.
   Google Scholar
• Dejana E, Brenario F, Erroi A, et al: Modulation of endothelial cell function by different molecular species of interleukin-1. Blood 69:635–699, 1987.
   Google Scholar
• Caverzasio J, Rizzoli R, Dayer JM: Interleukin-1 decreases renal sodium reabsorption: Possible mechanisms of endotoxin-induced natriuresis. Am J Physiol 252:943–6, 1987.
   PubMed Web of Science ®Google Scholar
• Gulick T, Chung MK, Pieper SJ, et al: Interleukin-1 and tumor necrosis fac-tor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA 86:6753–6757, 1989.
   PubMed Web of Science ®Google Scholar
• Cannon JG, Angel JB, Abad LW, Vannier E, Mileno MD, Fagioli L, Wolff SM, Komaroff AL: Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. Journal of Clini-cal Immunology 17(3):253–261, 1997.
   Google Scholar
• Beutler B, Cerami A: Cachectin (tumor necrosis factor). A macrophage hor-mone governing cellular metabolism and inflammatory response. Endocr Rev 9:57–66, 1988.
   Google Scholar
• Kriegler M, Perez C, DeFay, et al: A novel form of TNF-cachectin in a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNE Cell 53:45-53, 1988.
   Google Scholar
• Wilt SG, Milward E, Zhou JM, et al.: In vitro evidence for a dual role of tumor necrosis factor in human immunodeficiency virus type 1 encephalopathy. Ann Neurol 37:381-394, 1995.
   Google Scholar
• Dreisbach AW, Hendrickson T, Beezhold D, Riesenberg LA, Sklar AH: Ele-vated levels of tumor necrosis factor alpha in postdialysis fatigue. International Jour-nal of Artificial Organs 21(2):83–86, 1998.
   PubMed Web of Science ®Google Scholar
• Dinarello C: Interleukin-1 and tumor necrosis factor: Effector cytokines in autoimmune diseases. Seminars Immunol 4(3):133–145, 1992.
   Google Scholar
• Watson J, Mochizuki D: Interleukin-2: a class of T cell growth factor. Immu-nol Rev 51:257–278, 1980.
   PubMedGoogle Scholar
• Fletcher M, Goldstein AL: Recent advances in the understanding of the bio-chemistry and clinical pharmacology of interelukin-2. Lymphokine Res 1:45–57, 1987.
   Google Scholar
• Morgan DA, Ruscetti FW, Gallo RC: Selective in vitro growth of T lympho-cytes from normal human bone marrows. Science 193:1007–1008, 1976.
   PubMed Web of Science ®Google Scholar
• Malkovsky M, Loveland B, Noth M, et al: Recombinant interleukin-2 direct-ly augments the cytotoxicity of human monocytes. Nature 325:262–265, 1987.
   PubMed Web of Science ®Google Scholar
• Tsudo M, Ichiyama T, Uchino H: Expression of Tac antigen on activated normal human B cells. J Exp Med 160:612–617, 1984.
   PubMed Web of Science ®Google Scholar
• Cheney PR, Dorman SE, Bell DS: Interleukin-2 and the chronic fatigue syn-drome. Ann Intern Med 110(4):321, 1989.
   Google Scholar
• Cohen N, Stempel C, Colombe B, et al: Soluble interleukin-2 receptor: detection and potential role in organ transplantation. Clinical Immunology Newslet-ter 10(12):175, 1990.
   Google Scholar
• Pui CH: Serum interleukin-2 receptor: clinical and biological implications. Leukemia 3(5):323–327, 1989.
   Google Scholar
• Paul WE, Ohara J: B-cell stimulatory factor-1/interleukin-4. Annu Rev Im-munol 5:429–459, 1987.
   PubMed Web of Science ®Google Scholar
• Kuehn R, Rajewsky K, Mueller W: Generation and analysis of interlekin-4 deficient mice. Science 254:713–716, 1991.
   PubMedGoogle Scholar
• Chao CC, Gallagher M, Phair J, Peterson PK: Serum neopterin and interleu-kin-6 levels in chronic fatigue syndrome. J Infect Dis 162:1412–1413, 1990.
   PubMed Web of Science ®Google Scholar
• Chao CC, Janoff EN, Hu S, Thomas K, Gallagher M, Tsang M, Peterson PK: Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine 3:292–298, 1991.
   PubMed Web of Science ®Google Scholar
• Mizel SB: The interleukins. FASEB J 3:2379–2388, 1989.
   PubMed Web of Science ®Google Scholar
• Van Snick J: Interleukin-6: an overview. Ann Rev Immunol 8:253–278, 1990.
   PubMed Web of Science ®Google Scholar
• Penttila IA, Harris RJ, Storm P, Haynes D, Worswick DA, Marmion BP: Cy-tokine dysregulation in the post-Q-fever syndrome. QJM 91(8):549–560, 1998.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Hanna DA, Wakefield D: Interferon and myalgic encephalomyeli-tis. Lancet 1:471, 1988.
   PubMed Web of Science ®Google Scholar
• Ho-Yen DO, Carrington D, Armstrong AA: Myalgic encephalomyelitis and alpha-interferon. Lancet 1:125, 1988.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Mock V, Hawkins MJ: Fatigue: Definitions, mechanisms, and paradigms for study. Seminars in Oncology 1998; 25(1 Suppl 1):48–53, 1998.
   Google Scholar
• Jones TH, Wadler S, Hupart KH: Endocrine-mediated mechanisms of fa-tigue during treatment with interferon-alpha. Seminars in Oncology 25(1 Suppl 1): 54–63, 1998.
   Google Scholar
• Pavol MA, Meyers CA, Rexer JL, et al.: Pattern of neurobehavioral deficits with interferon alpha tehrapy for leukemia. Neurology 45:947–950, 1995.
   PubMed Web of Science ®Google Scholar
• Davis JM, Weaver JA, Kohut ML, Colbert LH, Ghaffar A, Mayer EP: Im-mune system activation and fatigue during treadmill running: Role of interferon. Medi-cine & Science in Sports & Exercise 30(6):863–868, 1998.
   PubMed Web of Science ®Google Scholar
• Zlotnick A, Shimonkewitz P, Gefter ML, et al: Characterization of the gam-ma interferon-mediated induction of antigen-presenting ability in P388D cells. J Im-munol 131:2814–2820, 1983.
   PubMed Web of Science ®Google Scholar
• Targan S, Stebbing N: In vitro interactions of purified cloned human inter-ferons on NK cells: enhanced activation. J Immunol 129:934–935, 1982.
   PubMed Web of Science ®Google Scholar
• Knop J, Stremer R, Nauman C, et al: Interferon inhibits the suppressor T cell response of delayed hypersensitivity. Nature 296:757–759, 1982.
   PubMed Web of Science ®Google Scholar
• Bennett AL, Chao CC, Hu S, Buchwald D, Fagioli LR, Schur PH, Peterson PK, Komaroff AL: Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. Journal of Clinical Immunology 17(2):160–166, 1997.
   PubMed Web of Science ®Google Scholar
• Bagasra 0, Fitzharis JW, Bagasra TT: Neopterin: an early marker of devel-opment of pre-AIDS conditions in HIV-seropositive individuals. Clinical Immunolo-gy Newsletter 9:197–199, 1988.
   Google Scholar
• Patarca R: Pteridines and neuroimmune function and pathology. Journal of Chronic Fatigue Syndrome 3(1):69–86, 1997.
   Google Scholar
• Fuchs D, Muur C, Reibnegger G, Weiss G, Werner ER, Werner-Felmayer G, Wachter H: Nitric oxide synthase and antimicrobial armature of human macro-phages. J Inf Dis 169:224, 1994.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Baier-Bitterlich G, Wachter H: Nitric oxide and AIDS dementia. New Eng J Med 333(8):521–522, 1995.
   PubMed Web of Science ®Google Scholar
• Baier-Bitterlich G, Fuchs D, Murr C, Reibnegger G, Werner Felmayer G, Sgonc R, Bock G, Dierich MP, Wachter H: Effect of neopterin and 7,8-dihydroneop-terM on tumor necrosis factor-alpha induced programmed cell death. FEBS Lett 364:234–238, 1995.
   PubMed Web of Science ®Google Scholar
• Lutgendorf S, Antoni MH, Ironson G, Fletcher MA, Penendo F, Van Riel F, Baum A, Schneiderman N, Klimas N: Physical symptoms of chronic fatigue syn-drome are exacerbated by the stress of Hurricane Andrew. Psychosomatic Med 57:310–323, 1995.
   PubMed Web of Science ®Google Scholar
• Fuchs D, Moller AA, Reibnegger G, et al: Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J AIDS 3:873–876, 1990.
   PubMed Web of Science ®Google Scholar
• Iwagaki H, Hizuta A, Tanaka N, Orita K: Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin. Immuno-logical Investigations 24(3):467–478, 1995.
   PubMed Web of Science ®Google Scholar
• Heyes MP, Saito K, Milstein S, Schiff SJ: Quinolinic acid in tumors, hemor-rhage and bacterial infections of the central nervous system in children. J Neurol Sci 133(1-2):112–118, 1995.
   PubMed Web of Science ®Google Scholar
• Saito K: Biochemical studies on AIDS dementia complex-possible con-tribution of quinolinic acid during brain damage. Rinsho Byori-Jap J Clin Pathol 43(9):891–901, 1995.
   PubMedGoogle Scholar
• Shaskan EG, Brew BJ, Rosenblum M, Thompson RM, Price RW: Increased neopterin levels in brains of patients with human immunodeficiency virus type 1 in-fection. J Neurochem 59(4):1541–1546, 1992.
   Google Scholar
• Andondonskaja-Renz B, Zeitler H: Pteridines in plasma and in cells of pe-ripheral blood tumor patients. In Biochemical and clinical aspects of pteridines, Pfeiderer W, Wachter H, Curtius HC (eds.). Berlin-New York, Walter de Gruyter, 1984, pp. 295–311.
   Google Scholar
• Sonnerborg A, SaafJ, Alexius Bet al: Quantitative detection of brain aberra-tions in human immunodeficiency virus type 1-infected individuals by magnetic res-onance imaging. J Inf Dis 162:1245–1251, 1990.
   PubMed Web of Science ®Google Scholar
• Buchwald D, Cheney PR, Peterson DL, Henry B, et al: Chronic illness char-acterized by fatigue, neurologic and immunologic disorders and active human her-pesvirus 6 type infection. Ann Int Med 116:103–113, 1992.
   PubMed Web of Science ®Google Scholar
• Hamblin TJ, Hussain J, Akbar AN, et al: Immunological reason for chronic ill health after infectious mononucleosis. BMJ 287:85–88, 1983.
   PubMed Web of Science ®Google Scholar
• Tosato G, Straus S, Henle W, et al: Characteristic T cell dysfunction in pa-tients with chronic active Epstein-Barr virus infection (chronic infectious mononu-cleosis). J Immunol 134:3082–3088, 1985.
   PubMed Web of Science ®Google Scholar
• Hilgers A, Frank J: Chronic fatigue syndrome: Evaluation of a 30-criteria-score and correlation with immune activation. Journal of Chronic Fatigue Syndrome 2(4):35–47, 1996.
   Google Scholar
• Read R, Spickett G, Harvey J, et al: IgG1 subclass deficiency in patients with chronic fatigue syndrome. lancet 1:241–242, 1988.
   PubMed Web of Science ®Google Scholar
• Roubalova K, Roubal J, Skopovy P, et al: Antibody response to Epstein-Barr virus antigens in patients with chronic viral infection. J Med Viol 25:115–122, 1988
   PubMed Web of Science ®Google Scholar
• Salit IE: Sporadic postinfectious neuromyasthenia. Can Med Assoc J 133: 659–663, 1985.
   PubMed Web of Science ®Google Scholar
• Wakefield D, Lloyd A, Brockman A: Immunoglobulin subclass abnormali-ties in patients with chronic fatigue syndrome. J Pediatr Infect Dis 9(8):550–553, 1990.
   Google Scholar
• Komaroff AL, Geiger AM, Wormsley S: IgG subclass deficiencies in chron-ic fatigue syndrome. Lancet 1:1288–1289, 1988.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Hickie I, Wakefield D, et al: A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syn-drome. Am J Med 89:561–568, 1990.
   PubMed Web of Science ®Google Scholar
• Peterson PK, Shepard J, Macres M, et al: A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med 89:554–560, 1990.
   PubMed Web of Science ®Google Scholar
• Rowe KS: Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in ado-lescents. Journal of Psychiatric Research 31(1):133–147, 1997.
   PubMed Web of Science ®Google Scholar
• Straus SE: Intravenous immunoglobulin treatment for the chronic fatigue syndrome. Am J Med 89:551–553, 1990.
   PubMed Web of Science ®Google Scholar
• Vollmer-Conna U, Hickie I, Hadzi-Pavlovic D, Tymms K, Wakefield D, Dwyer J, Lloyd A: Intravenous immunoglobulin is ineffective in the treatment of pa-tients with chronic fatigue syndrome. American Journal of Medicine 103(1):38–43, 1997.
   PubMed Web of Science ®Google Scholar
• Bennett AL, Fagioli LR, Schur PH, Schacterle RS, Komaroff AL: Immuno-globulin subclass levels in chronic fatigue syndrome. Journal of Clinical Immunolo-gy 16(6):315–320, 1996.
   PubMed Web of Science ®Google Scholar
• Konstantinov K, von Mikecz A, Buchwald D, Jones J, Gerace L, Tan EM: Autoantibodies to nuclear antigens in chronic fatigue syndrome. Journal of Clinical Investigation 98(8):1888–1896, 1996.
   PubMed Web of Science ®Google Scholar
• Poteliakhoff A: Fatigue syndromes and the aetiology of autoimmune dis-ease. Journal of Chronic Fatigue Syndrome 4(4):31–50 1998.
   Google Scholar
• von Mikecz A, Konstantinov K, Buchwald DS, Gerace L, Tan EM: High fre-quency of autoantibodies in patients with chronic fatigue syndrome. Arthritis & Rheumatism 40(2):295–305, 1997.
   PubMed Web of Science ®Google Scholar
• Keller RH, Lane JL, Klimas N, Reiter WM, Fletcher MA, van Riel F, Mor-gan R: Association between HLA class II antigens and the chronic fatigue immune dysfunction syndrome. Clin Inf Dis 18(Suppl 1):5154–5156, 1994.
   Google Scholar
• Kaslow JE, Rucker L, Onishi R: Liver extract-folic acid-cyanocobalamin vs. placebo for chronic fatigue syndrome. Arch Intern Med 149:2501–2503, 1989.
   Google Scholar
• Bates DW, Buchwald D, Lee J, Kith P, Doolittle T, Rutherford C, Churchill WH, Schur PH, Werner M, Wybenga D, et al: Clinical laboratory test findings in pa-tients with chronic fatigue syndrome. Arch of Intern Med 155:97–103, 1995.
   PubMed Web of Science ®Google Scholar
• Nishikai M, Kosaka S: Incidence of antinuclear antibodies in Japanese pa-tients with chronic fatigue syndrome. Arthritis & Rheumatism 40(11):2095–2097, 1997.
   PubMed Web of Science ®Google Scholar
• Weinstein L: Thyroiditis and "chronic infectious mononucleosis." N. Engl J Med 317:1225–1226, 1987.
   PubMed Web of Science ®Google Scholar
• Plioplys AV: Antimuscle and anti-CNS circulating antibodies in chronic fa-tigue syndrome. Neurology 48(6):1717–1719, 1997.
   PubMed Web of Science ®Google Scholar
• Cohen S, Tyrrell DA, Smith AP: Psychological stress and susceptibility to the common cold. N Eng J Med 325(9):606–612, 1991.
   PubMed Web of Science ®Google Scholar
• Glaser R, Rabin B, Chesney M, Cohen S, Natelson B: Stress-associated im-mune modulation: implications for infectious diseases? JAMA 281(24):2268–2270, 1999.
   Google Scholar